Other substances

Triazavirin

A guanine nucleotide analogue.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
2
 Clinical trials

General information

Triazavirin is a guanine nucleotide analogue displaying anti-influenza activity (DrugBank).

Triazavirin on PubChem
Triazavirin on Wikipedia


Synonyms

TZV; Riamilovir

 

Structure image - Triazavirin

CSC1=NC2=NN=C(C(=O)N2N1)[N+](=O)[O-]

Supporting references

Link Tested on Impact factor Notes Publication date
Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial
Small molecule Randomized controlled double-blind trial 		Patients 6.50

No-statistically significant improvement in the Triazavirin-treated group within the primary outcome. Numerically, more patients in the treated group reached the primary outcome and less frequently needed the usage of certain additional medication, however. Sample size: 26 + 26 placebo. Dosage: 250 mg tree to four times a day for 7 days. Endpoint: Clinical improvement (normalization of body temperature, respiratory rate, oxygen saturation, cough, and absorption of pulmonary infection by chest computed tomography (CT) until 28 days after randomization) (primary outcome).



 Sep/08/2020

AI-suggested references

Link Publication date
Triazavirin - Potential Inhibitor for 2019-nCoV Coronavirus M Protease: A DFT Study.
May/22/2020
[The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis].
Oct/13/2021
The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol.
Jul/03/2020
On a knife's edge of a COVID-19 pandemic: is containment still possible?
Mar/09/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04973462 Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19 Recruiting Phase 4 Aug/01/2021 Dec/30/2021
  • Alternative id - Antiviral therapy in COVID-19
  • Interventions - Drug: standard treatment COVID-19 + Triazavirin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Fever Hospital of the Egyptian Armed Forces, Cairo, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - Physicians Global Assessment to measure the baseline COVID-19 signs and symptoms|Time to recovery|Incidence of re-detection of viral RNA using PCR|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
NCT04581915 PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Recruiting Phase 2|Phase 3 Sep/08/2020 Dec/31/2021
  • Alternative id - PHRU CoV01
  • Interventions - Drug: Triazavirin (Riamilovir)|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The Perinatal HIV Research Unit - Matlosana, Klerksdorp, North West Province, South Africa
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 420
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - To compare the slope of cycle threshold(Ct) values of nasopharyngeal swabs in people receiving Triazavirin versus placebo|To assess the proportion of patients who progress to severe COVID-19 and the proportion who need ICU or die.|To determine the proportion of patients who develop grade 3 or grade 4 adverse events on treatment|To determine the proportion of patients who stop taking either placebo/Triazavirin
Export (.csv)